Closing Thoughts On US FDA Advisory Committee Reforms

 
• By Michael McCaughan

One speaker at the US FDA’s day-long “listening session” on advisory committee reform captured an important truth: the problem is not necessarily how committees are run, it is that there are no alternatives for public input into agency decisions.

Window into empty store
The FDA may need a larger window into its decision-making. • Source: Shutterstock

The US Food and Drug Administration’s day-long “listening session” on ideas to reform the advisory committee process bore an uncanny resemblance to the regular open public hearing in those meetings.

Key Takeaways

  • The FDA’s advisory committee reform meeting sounded a lot like an advisory committee meeting’s open public hearing.

More from US FDA Performance Tracker

More from Regulatory Trackers